Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine 5 mg vs 10 mg for prevention of chemotherapy-induced nausea and vomiting without NK1 antagonist
TCTR20200708006Phase 3Completed
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV), sponsored by None. Started Jun 2020; status: completed.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on TCTR20200708006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200708006.